Halozyme Therapeutics (NASDAQ:HALO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday morning.

A number of other brokerages have also recently commented on HALO. Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $83.00 to $110.00 in a research note on Friday. UBS Group reiterated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Morgan Stanley decreased their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Trading Down 0.5%

Shares of HALO stock opened at $102.62 on Friday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $104.77. The firm’s 50 day moving average price is $77.17 and its two-hundred day moving average price is $71.70. The stock has a market cap of $12.17 billion, a price-to-earnings ratio of 30.63, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter last year, the firm posted $1.54 EPS. The business’s revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts anticipate that Halozyme Therapeutics will post 7.54 EPS for the current year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the transaction, the director owned 42,044 shares of the company’s stock, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,477 shares of company stock worth $3,667,643 over the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently made changes to their positions in HALO. Arrowstreet Capital Limited Partnership grew its position in shares of Halozyme Therapeutics by 29.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after buying an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock valued at $141,613,000 after acquiring an additional 25,731 shares in the last quarter. Norges Bank acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at $128,201,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics during the 4th quarter valued at $124,031,000. Finally, Federated Hermes Inc. boosted its stake in Halozyme Therapeutics by 8.5% during the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after acquiring an additional 123,917 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.